EczemaPred: a computational framework for personalised prediction of eczema severity dynamics
File(s)
Author(s)
Type
Journal Article
Abstract
Background:
Atopic dermatitis (AD) is a chronic inflammatory skin disease leading to substantial quality of life impairment with heterogeneous treatment responses. People with AD would benefit from personalised treatment strategies, whose design requires predicting how AD severity evolves for each individual.
Objective:
This study aims to develop a computational framework for personalised prediction of AD severity dynamics.
Methods:
We introduced EczemaPred, a computational framework to predict patient-dependent dynamic evolution of AD severity using Bayesian state-space models that describe latent dynamics of AD severity items and how they are measured. We used EczemaPred to predict the dynamic evolution of validated patient-oriented scoring atopic dermatitis (PO-SCORAD) by combining predictions from the models for the nine severity items of PO-SCORAD (six intensity signs, extent of eczema, and two subjective symptoms). We validated this approach using longitudinal data from two independent studies: a published clinical study in which PO-SCORAD was measured twice weekly for 347 AD patients over 17 weeks, and another one in which PO-SCORAD was recorded daily by 16 AD patients for 12 weeks.
Results:
EczemaPred achieved good performance for personalised predictions of PO-SCORAD and its severity items daily to weekly. EczemaPred outperformed standard time-series forecasting models such as a mixed effect autoregressive model. The uncertainty in predicting PO-SCORAD was mainly attributed to that in predicting intensity signs (75% of the overall uncertainty).
Conclusions:
EczemaPred serves as a computational framework to make a personalised prediction of AD severity dynamics relevant to clinical practice. EczemaPred is available as an R package.
Atopic dermatitis (AD) is a chronic inflammatory skin disease leading to substantial quality of life impairment with heterogeneous treatment responses. People with AD would benefit from personalised treatment strategies, whose design requires predicting how AD severity evolves for each individual.
Objective:
This study aims to develop a computational framework for personalised prediction of AD severity dynamics.
Methods:
We introduced EczemaPred, a computational framework to predict patient-dependent dynamic evolution of AD severity using Bayesian state-space models that describe latent dynamics of AD severity items and how they are measured. We used EczemaPred to predict the dynamic evolution of validated patient-oriented scoring atopic dermatitis (PO-SCORAD) by combining predictions from the models for the nine severity items of PO-SCORAD (six intensity signs, extent of eczema, and two subjective symptoms). We validated this approach using longitudinal data from two independent studies: a published clinical study in which PO-SCORAD was measured twice weekly for 347 AD patients over 17 weeks, and another one in which PO-SCORAD was recorded daily by 16 AD patients for 12 weeks.
Results:
EczemaPred achieved good performance for personalised predictions of PO-SCORAD and its severity items daily to weekly. EczemaPred outperformed standard time-series forecasting models such as a mixed effect autoregressive model. The uncertainty in predicting PO-SCORAD was mainly attributed to that in predicting intensity signs (75% of the overall uncertainty).
Conclusions:
EczemaPred serves as a computational framework to make a personalised prediction of AD severity dynamics relevant to clinical practice. EczemaPred is available as an R package.
Date Issued
2022-03-28
Date Acceptance
2022-03-14
Citation
Clinical and Translational Allergy, 2022, 12 (3)
ISSN
2045-7022
Publisher
BioMed Central
Journal / Book Title
Clinical and Translational Allergy
Volume
12
Issue
3
Copyright Statement
© 2022 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
License URL
Sponsor
British Skin Foundation
PIERRE FABRE DERMOCOSMETIQUE
FONDATION ECZEMA
ASSOCIATION CENTRE NANTAIS DE RESERCHE APPLIQUÉE AUX AFFECTIONS CUTANÉES
Grant Number
005/R/18
STDD 1965986-1
N/A
N/A
Subjects
Science & Technology
Life Sciences & Biomedicine
Allergy
atopic dermatitis
Bayesian model
machine learning
PO-SCORAD
prediction
HARMONIZING OUTCOME MEASURES
PATIENT-ORIENTED SCORAD
ATOPIC ECZEMA
DERMATITIS
STATEMENT
SYMPTOMS
AREA
Bayesian model
PO-SCORAD
atopic dermatitis
machine learning
prediction
Publication Status
Published
Article Number
ARTN e12140
Date Publish Online
2022-03-28